Windtree Therapeutics, Inc.

NasdaqCM:WINT Voorraadrapport

Marktkapitalisatie: US$6.3m

Windtree Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Windtree Therapeutics has been growing earnings at an average annual rate of 9.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 99.7% per year.

Belangrijke informatie

9.8%

Groei van de winst

39.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei-99.7%
Rendement op eigen vermogen-325.8%
Nettomargen/a
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Dec 06

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Jul 06

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Jun 09
Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Feb 09
Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Opbrengsten en kosten

Hoe Windtree Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:WINT Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-11817
31 Mar 240-699
31 Dec 230-2098
30 Sep 230-25106
30 Jun 230-24106
31 Mar 230-35107
31 Dec 220-391111
30 Sep 220-431214
30 Jun 220-471217
31 Mar 220-671318
31 Dec 210-681418
30 Sep 210-621529
30 Jun 210-631524
31 Mar 210-351520
31 Dec 200-331415
30 Sep 200-32130
30 Jun 200-31130
31 Mar 200-27120
31 Dec 190-27120
30 Sep 191-43130
30 Jun 191-40110
31 Mar 192-3790
31 Dec 182-3570
30 Sep 182-960
30 Jun 181-1360
31 Mar 181-1770
31 Dec 171-2570
30 Sep 172-3470
30 Jun 173-3570
31 Mar 172-3870
31 Dec 162-3970
30 Sep 162-4380
30 Jun 161-5680
31 Mar 161-57100
31 Dec 151-55110
30 Sep 152-56130
30 Jun 152-45150
31 Mar 153-45160
31 Dec 143-44170
30 Sep 142-45170
30 Jun 141-46170
31 Mar 140-44170
31 Dec 130-45170

Kwaliteitswinsten: WINT is currently unprofitable.

Groeiende winstmarge: WINT is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: WINT is unprofitable, but has reduced losses over the past 5 years at a rate of 9.8% per year.

Versnelling van de groei: Unable to compare WINT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: WINT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: WINT has a negative Return on Equity (-325.82%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden